StockData
CASI Pharmaceuticals, Inc. logo

CASI Pharmaceuticals, Inc. (CASIF) stock

CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on May 15, 2026Score 1/30
$0.10+0.00 (0.00%)

Close on Oct 19, 2026Market cap –P/E –Yield –

Earnings

CASI Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q4 FY2023
$6.90M
EPS, Q4 FY2023
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of CASI Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2023ended Dec 31, 2023Mar 28, 2024during market hours$6.90M––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

CASI Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When CASI Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases CASI Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?